ctix pr excerpts - mostly with research hospital theme - exploration of Buccaneers post1945 - I agree with Buc - I think DF/BI scientists are excited!
"It has taken a significant amount of time, even longer than we had originally expected, but what was unforeseeable was the lengthy review process at the world’s leading cancer research center. It is an arduous task, to say the least. Understand that it is representatives from member hospitals that will be involved in the clinical trials that must review the data and agree to host the human trials. They are very thorough in their due diligence and selective as to which companies and compounds they will research. We could have gone with many different, less prestigious hospitals, but given that our research has shown that Kevetrin holds unparalleled potential, we wanted to go with the absolute best and we feel that the extra time was well-warranted."
The key reason why the hospital chose Kevetrin for clinical trials among the many requests it gets is due to Kevetrin’s unique method of action, p53, also known as the “guardian angel gene.” So, yes, we would certainly say that it is extremely rare and speaks volumes about the quality of not only Kevetrin as a potential ground-breaking cancer therapy, but Cellceutix as a company.
Dana-Farber is one of the few hospitals in the world that collects data ‘mapping’ the human genome as related to tumor profiling and the information that will be collected from our clinical trials of Kevetrin™ could prove an invaluable asset to those suffering from cancer and to Cellceutix.”
“It is quite a milestone accomplishment to have major universities and hospitals beginning to study our compound,” said Leo Ehrlich, Chief Executive Officer at Cellceutix. “Other parties and grants will cover the cost of the study. There are many benefits to working with a member of the premier university hospital in the world. Beth Israel Deaconess Medical Center will be researching Kevetrin™ for indications in addition to those which we will be studying in our company-sponsored clinical trials. If they collect promising data in their research of Kevetrin™ in melanoma and renal cell carcinoma, additional grant and government funding may become available to further study these separate indications, saving us substantial time and money towards the end goal of commercialization.”
Cellceutix formed a collaborative agreement with Beth Israel Deaconess Medical Center for combination studies with multikinase inhibitors, under development from a large pharmaceutical manufacturer, which activate pro-apoptotic activity by translocation of p53 in mitochondria and inducing apoptosis. This study will provide vital insight to exploit the nuclear and/or mitochondrial pro-apoptotic function by Kevetrin in combination with other multikinase inhibitors in treatment of these malignancies.
we plan that at the conclusion of the Phase 1 to choose a cancer for fast track with a Phase 2/3 application. In addition, the strategy would be to select another cancer which would qualify as an orphan drug for Phase 2/3 studies.
